FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL										
l	OMB Number:	3235-0287									
l	Estimated average burden										
l	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or Se	ction 30(h)	of the	Investmen	it Cor	mpany Act	of 19	40							
ı	nd Address of		2. Issuer Name and Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [LPTX]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner							
(Last) (First) (Middle) 51 ASTOR PLACE, 10TH FLOOR						3. Date of Earliest Transaction (Month/Day/Year) 09/24/2021									Officer (g below)	give title		Other (below)	specify
(Street) NEW YORK NY 10003					4. If Amendment, Date of Original Filed (Month/Day/Year)										Form file	oint/Group Filing		ting Persor	
(City)	?)	State)	(Zip)											X	r om me	u by wo	Culair	one repor	ung i craon
		7	able I - Non	-Deriva	tive S	Securitie	s A	cquired,	Dis	posed (of, o	r Ben	efici	ally	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr.				ties Acquired (A) o I Of (D) (Instr. 3, 4			5. Amount Securities Beneficiall Owned Fol Reported	у	Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	ount (A) or (D)		Pri	се	Transaction(s) (Instr. 3 and 4)				(111541. 4)
			Table II - E			curities Ills, warr									wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisal Expiration Date (Month/Day/Year		7. Title and Amo Securities Under Derivative Secur (Instr. 3 and 4)		nderly ecurit	/ing	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securiti Benefici Owned Followir Reporte	ve es ially ng d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownershi t (Instr. 4)
				Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	1	mour lumbe shares	r of		Transac (Instr. 4)			
Warrants (right to buy) \$0.001		09/24/2021		P		3,508,771		(1)	(1)			nmon ock	3,508,771		\$2.849	3,508,771		I	See footnote ⁽²⁾
1. Name ar																			
(Last) 51 ASTO	OR PLACE	(First) 10TH FLOOR	(Middle)																
(Street) NEW Y	ORK	NY	10003																
(City)		(State)	(Zip)																
ı		Reporting Person [*]		ER FU	<u>JND</u>														
(Last) 51 ASTO	OR PLACE	(First) , 10TH FLOOR	(Middle)																
(Street) NEW YORK		NY 10003																	
(City)		(State)	(Zip)			_													
ı	nd Address of	Reporting Person*																	
(Last) 51 ASTO	OR PLACE	(First) , 10TH FLOOR	(Middle)																
(Street) NEW YORK NY		NY	10003																

Explanation of Responses:

(State)

(Zip)

(City)

- 1. The pre-funded warrants are immediately exercisable, provided that the warrants may not be exercised if the holder and its affiliates would beneficially own in excess of 4.99% of the Issuer's common stock outstanding after giving effect to the exercise.
- 2. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of

his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other

/s/ Joseph Edelman - for Perceptive Life Sciences Master

Fund Ltd., By: Perceptive Advisors LLC, its investment

manager, By: Joseph Edelman,

its managing member /s/ Joseph Edelman - for

Perceptive Advisors LLC, By: Joseph Edelman, its managing

09/28/2021

09/28/2021

member

/s/ Joseph Edelman 09/28/2021 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.